Adamas Pharma (ADMS): ADS-5102 Pricing Could Be Higher Than Expected, Raising PT - Mizuho

September 8, 2016 6:31 AM EDT
Get Alerts ADMS Hot Sheet
Price: $16.29 +0.18%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 20 | New: 54
Trade ADMS Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Mizuho Securities analyst, Irina Koffler. reiterated her Buy rating Adamas Pharmaceuticals (NASDAQ: ADMS) and raised her price target to $26 from $22 after a recent deal in the Parkinson's space indicates pricing for ADS-5102 could be higher than expected.

The next event for the company is the ADS-5102 NDA submission in late 2016.

For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.

Shares of Adamas Pharmaceuticals closed at $15.63 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Irina Koffler

Add Your Comment